


Figure 1 Cytotoxicity profile on A549 cells of ColoAd1 in the presence of fresh whole human blood for donors A-I




Figure 2 Biodistribution of 1e11 ($1x10^{11}$) particles of ColoAd1 in normal BalbC mice 24 hours post injection





Figure 3 Biodistribution of ColoAd1 and ColoAd1CJ132 in CD46 transgenic mice at 1 hr and 72 hrs post-injection

Figure 4 Clearance kinetics of ColoAd1 from primary organs liver, spleen and lungs in CD46-expressing mice followed for 65 days



* Below limit of detection





Figure 5 Kinetics of ColoAd1 in mice either with or without co-administration of neutralising serum

Figure 6 Cytokine levels after the first and subsequent equal therapeutic doses in a pre-clinical toxicology study in CD-1 mice:






Figure 7A TNF (A) Cytokine levels (ng/L) over time in human cancer patients with metastatic solid epithelial tumours after intravenous doses of ColoAd1.




Figure 7B Ggamma interferon Cytokine levels (ng/L) over time in human cancer patients with metastatic solid epithelial tumours after intravenous doses of ColoAd1.




Figure 7C IL6 Cytokine levels (ng/L) over time in human cancer patients with metastatic solid epithelial tumours after intravenous doses of ColoAd1.




Figure 8A Systemic pharmacokinetics of ColoAd1 (mean DNA copies per mL of blood) in 3 human cancer patients with metastatic solid epithelial tumours. Patients were dosed with $1x10^{12}$ viral particles per dose administered at $2x10^{11}$ viral particles/min on Days 1, 3 and 5




Figure 8B Systemic pharmacokinetics of ColoAd1 (DNA copies per mL of blood) in human cancer patients with metastatic solid epithelial tumours.




Figure 9A-B Systemic pharmacokinetics of ColoAd1 (Genome copies per mL of blood) in human cancer patients administered with 1e10 ($1x10^{10}$) (A) and 1e11 ($1x10^{11}$) (B) ColoAd1 viral particles over 5 minutes.





Figure 9C-D Systemic pharmacokinetics of ColoAd1 (Genome copies per mL of blood) in human cancer patients administered with 1e12 ($1x10^{12}$) (C) and 1e13 ($1x10^{13}$) (D) ColoAd1 viral particles over 5 minutes.







Figure 9E-F Systemic pharmacokinetics of ColoAd1 (Genome copies per mL of blood) in human cancer patients administered with 3e12 ($3x10^{12}$) (E) viral particles over 5 minutes and 3e12 ($3x10^{12}$) (F) ColoAd1 viral particles over 20 minutes.

Figure 9G Systemic pharmacokinetics of ColoAd1 (Genome copies per mL of blood) in human cancer patients administered with 6e12 ($6x10^{12}$) ColoAd1 viral particles over 40 minutes.






Figure 10 Slower infusion of the same dose lowers the cMax level at the end of infusion (cohort 5 vs 6)




Figure 11 – Comparison of mean plasma levels of MCP1 for each dose cohort




Figure 12 – ColoAd1 replication cycle




Figure 13 ColoAd1 infection of cancer cells shown as nuclear staining in a colorectal cancer cell line following in vitro infection with the virus




Figure 14 A-D. ColoAd1 IT administration, hexon (A) and isotype control (B) staining; ColoAd1 IV administration hexon (C) and isotype control (D) staining respectively





Figure 15 **320 clinically approved or developed compounds were analysed for their impact on virus replication**

Relative fold change in replication over ColoAd1 virus alone

Figure 16 *In vivo* Model – Paclitaxel / ColoAd1 combination therapy (Day 33)

A - PBS



B - Paclitaxel






Figure 16 continued

C - ColoAd1



D ColoAd1 + Paclitaxel






Figure 17 ***In vivo*** **ColoAd1 / chemotherapy combination studies**




Figure 18 *In vivo* ColoAd1 / chemotherapy combination studies